Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

3D Printed Drugs Market by Spritam & Other Drugs Potential Market by Scenario - Global Forecast to 2030 - Research and Markets

Research and Markets
Posted on: 22 Dec 17

The "3D Printed Drugs Market by Spritam (U.S. and Rest of World) and Other Drugs Potential Market by Scenario (Rapid Growth Scenario, Moderate Growth Scenario, and Low Growth Scenario) - Global Opportunity Analysis and Industry Forecast, 2017-2030" report has been added to Research and Markets' offering.

Spritam is the only 3D printed drug which has received FDA approval. This drug was first available in the market in 2016, and can be used to treat epilepsy. The potential market for other 3D printed drugs (moderate growth scenario) is estimated to be $278 million in 2020, and would reach $522 million by 2030, growing at a CAGR of 6.5% from 2020 to 2030. 3D printed drugs are developed by 3D printing technology to treat patients and children affected with dysphagia. These drugs are highly porous in nature and disintegrate rapidly, which eliminate the need to directly swallow the intact high-dose medicine.

The growth of the 3D printed drugs market is driven by upsurge in demand of instantaneous soluble drugs, rise in geriatric population, and high adoption of 3D printing technology. In addition, rapid technological advancements, increase in awareness about the 3D printing, and improvement in healthcare infrastructure fuel the market growth. However, factors such as adverse effects related to these drugs, lack of government regulations for these drugs, and use of 3D printing to develop illegal drugs are expected to restrain the market growth. Conversely, introduction of 3D printed drugs by various key vendors in developing nations and increase in healthcare investment in emerging nations are expected to provide lucrative opportunities for the market growth in the near future.

Companies Mentioned

  • 3D Printer Drug Machine
  • Aprecia Pharmaceuticals
  • FabRx Ltd.
  • GlaxoSmithKline Plc.
  • Hewlett Packard Caribe, BV, LLC
  • National University of Singapore
  • The University of Nottingham
  • UCL School of Pharmacy
  • University College London
  • University of Glasgow

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Market Overview

4 Spritam: 3D Printed Drugs Market

5 Other 3D Printed Drugs Potential Market, by Scenario

6 Other 3D Printed Drugs Potential Market, by Region

7 Company Profiles

For more information about this report visit

View source version on

Business Wire

Last updated on: 22/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.